Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: Observational study data

British Journal of Ophthalmology

Volumn 99, Issue 3, 2015, Pages 359-364

  Barthelmes, Daniel ^a,b   Walton, Richard ^a   Campain, Anna E ^a   Simpson, Judy M ^c   Arnold, Jennifer J ^d   McAllister, Ian L ^e   Guymer, Robyn H ^f   Hunyor, Alex P ^a,g   Essex, Rohan W ^h   Morlet, Nigel ⁱ   Gillies, Mark ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Marsden Eye Specialists   (Australia)

^e LIONS EYE INSTITUTE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Retina Associates   (Australia)

^h CANBERRA HOSPITAL   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA TEAR; TREATMENT OUTCOME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; INTRAVITREAL DRUG ADMINISTRATION; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; SUBRETINAL FLUID; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; SUBRETINAL FLUID; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84923233916     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305514     Document Type: Article

References (25)

1. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
2. Martin DF, Maguire MG, Fine SL, et al.; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
3. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
4. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e1.
5. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-40.
6. Kovach JL, Schwartz SG, Flynn HW Jr, et al . Anti-VEGF Treatment Strategies for Wet AMD. J Ophthalmol 2012;2012:786870.
7. Castro-Correia J, Coutinho MF, Rosas V, et al . Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol 1992;81:379-86.
8. Hisatomi T, Sakamoto T, Murata T, et al. Relocalization of apoptosis-inducing factor in photoreceptor apoptosis induced by retinal detachment in vivo. Am J Pathol 2001;158:1271-8.
9. Ranty ML, Carpentier S, Cournot M, et al. Ceramide production associated with retinal apoptosis after retinal detachment. Graefes Arch Clin Exp Ophthalmol 2009;247:215-24.
10. Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology 1993;100:818-24; discussion 25.
11. Brown DM, Chen E, Mariani A Jr, et al. Super-dose anti-VEGF (SAVE) Trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point. Ophthalmology 2013;120:349-54.
12. Wykoff CC, Brown DM, Chen E, et al. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. Ophthalmic Surg Lasers Imaging Retina 2013;44:121-6.
13. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012;32:434-57.
14. Williams PD, Callanan D, Solley W, et al. A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol 2012;6:1519-25.
15. Yoshizawa C, Saito W, Hirose S, et al. Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration. Jpn J Ophthalmol 2013;57:68-73.
16. Gillies MC, Walton R, Liong J, et al. Efficient capture of high-quality data on outcomes of treatment for macular diseases: The Fight Retinal Blindness! Project. Retina 2014;34:188-95.
17. Gillies MC, Walton R, Simpson JM, et al. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Invest Ophthalmol Vis Sci 2013;54:5754-60.
18. Agresti A. An Introduction to Categorical Data Analysis. New York: John Wiley & Sons, Inc, 1996.
19. Cleveland WS, Grosse E, Shyu WM. Local regression models . Statistical Models in S: Wadsworth & Brooks/Cole, 1992.
20. R: A Language and Environment for Statistical Computing. Vienna, Austria: Foundation for Statistical Computing. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2013
21. Macular Photocoagulation Study Group. Occult choroidal neovascularization. Influence on visual outcome in patients with age-related macular degeneration. Arch Ophthalmol 1996;114:400-12.
22. Ying GS, Huang J, Maguire MG, et al.; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013;120:122-29.
23. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. Arch Ophthalmol 1991;109:1242-57.
24. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967;63(Suppl):1-139.
25. Brown DM, Tuomi L, Shapiro H. Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration. Retina 2013;33:23-34.